Sunday, January 26, 2020 5:11:11 PM
Generics bear the burden of proving patents are obvious.
Generics have to prove with “clear-and-convincing-evidence(s)”* that ALL patents are obvious.
* The evidence presented by a party during the trial must be highly and substantially more probable to be true than not and the trier of fact must have a firm belief or conviction in its factuality. It is a higher level of burden of persuasion than "preponderance of the evidence"
Amarin bear the burden of proving patent infringement.
Amarin has to prove with “burden of proof”** that Generics will induce infringement of (at least) ONE claim.
** The standard is met if the proposition is more likely to be true than not true. The standard is satisfied if there is greater than fifty percent chance that the proposition is true (preponderance of the evidence).
The Patents-In-Suit (Asserted Claims)
6 patents … 10 Claims are the topic.
U.S. Patent No. 8,293,728 (“the ‘728 Patent”), Claim 1 & Claim 16
U.S. Patent No. 8,318,715 (“the ‘715 Patent”), Claim 14
U.S. Patent No. 8,357,677 (“the ‘677 Patent”), Claim 1 & Claim 8
U.S. Patent No. 8,367,652 (“the ‘652 Patent”), Claim 1
U.S. Patent No. 8,431,560 (“the ‘560 Patent”), Claim 4 & Claim 17
U.S. Patent No. 8,518,929 (“the ‘929 Patent”), Claim 1 & Claim 5
(i) 3 Claims (‘728 Patent Claim 1* & 16, ‘715 Patent Claim 14*) are subject of “without concurrent lipid altering therapy” (*and “achieve the lipid effects required”
(ii) 6 Claims (‘677 Patent Claim 1 & 8, ‘652 Patent Claim 1, ‘560 Patent Claim 4 & 17, ‘929 Patent Claim 5) are subject of “achieve the lipid effects required” (without requirement of “without concurrent lipid altering therapy”)
(iii) All Claims are subject of “at least 12 weeks”;
arguments.
(i) “without concurrent lipid altering therapy”
Meanwhile the label (“14. Clinical Study”) contains information about statin usage (“Twenty-five percent of patients were on concomitant statin therapy”) it is silent about other concurrent lipid altering therapies, e.g., fibrates, niacin, and ezetimibe.
The “Clinical Pharmacology” section of the label reports studies on “Drug-Drug Interactions” between EPA and various concurrently administered drugs and states that EPA did not change the
pharmacokinetics or blood levels of “atorvastatin”. GV can safely be coadministered with a concurrent lipid altering therapy (with statin).
The label do not explicitly or implicitly instruct physicians to administer GV to a patient who is not on concurrent lipid altering therapy.
Generics’ labels do not encourage, recommend, or promote administering GV without concurrent lipid altering therapy. … no inducement exist in case of these (i) Claims.
(ii) “without concurrent lipid altering therapy”
It’s a close call …
- The label does not have to encourage all physicians it is sufficient that Generics' labels will encourage some physicians
- Inducement need not be premised on explicit instructions to perform the infringing method, where the proposed label
- “Indications and Usage” & “Dosage and Administration” section [Sections] vs. full label (package insert)
- plausible interpretation of the labelling that suggests the Court could find induced infringement
See more in Part 2 (here) about these (in connection with “12-weeks”)
Generics’ labels could encourage, recommend, or promote administering GV to achieve the lipid effects.
(iii) “at least 12 weeks”
The remaining claim is the ‘929 Patent Claim 1:
Conclusion: Amarin has to prove with “burden of proof” that Generics will induce infringement of (at least) one claim …
(i) Claims: will fail
(ii) Claims: Meanwhile the arguments is weaker than in case of the “12-week” these Claims could prevail, an inducement could be the case … but is a close call
(iii) Claim: Generics will induce infringement of ‘929 Patent Claim 1.
Best,
G
"There are some things money can't buy. … For these, there is AMRN."
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for
Recent AMRN News
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM